Arterial stiffness in HIV-infected patients receiving highly active antiretroviral therapy

Antiviral Therapy

Volumn 10, Issue 8, 2005, Pages 925-935

  Sevastianova, Ksenia ^a   Sutinen, Jussi ^a   Westerbacka, Jukka ^a   Ristola, Matti ^a   Yki Järvinen, Hannele ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; STAVUDINE;

ADULT; AORTA PRESSURE; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR DISEASE; DISEASE SEVERITY; FEMALE; HEART RATE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PULSE WAVE; TREATMENT DURATION;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AORTA; AORTIC DISEASES; ARTERIES; BLOOD; BLOOD PRESSURE; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HOSPITALS, TEACHING; HUMANS; MALE; PERIPHERAL VASCULAR DISEASES; SPHYGMOMANOMETERS;

EID: 30444456073     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ & Holmberg SD. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. New England Journal of Medicine 1998; 338:853-860.
2. Carr A & Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000; 356:1423-1430.
3. Grinspoon S & Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. New England Journal of Medicine 2005; 352:48-62.
4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ & Cooper DA. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
5. Carr A, Samaras K, Chisholm DJ & Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881-1883.
6. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ & Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor- associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353:2093-2099.
7. Friis-Møller N, Weber R, Reiss P, Thiebaut R, Kirk O, d'Arminio MA, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De WS, Sabin CA, Phillips AN & Lundgren JD. Cardiovascular disease risk factors in HIV patients - association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17:1179-1193.
8. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD & Sosman JM. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation 2001; 104:257-262.
9. Friis-Møller N, Sabin CA, Weber R, d'Arminio MA, El-Sadr WM, Reiss P, Thiebaut R, Morfeldt L, De WS, Pradier C, Calvo G, Law MG, Kirk O, Phillips AN & Lundgren JD. Combination antiretroviral therapy and the risk of myocardial infarction. New England Journal of Medicine 2003; 349:1993-2003.
10. Eckel RH, Grundy SM & Zimmet PZ. The metabolic syndrome. Lancet 2005; 365:1415-1428.
11. Bergersen BM, Sandvik L, Dunlop O, Birkeland K & Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naive and HIV-negative controls: results from a Norwegian study of 721 patients. European Journal of Clinical Microbiology and Infectious Diseases 2003; 22:731-736.
12. Chow DC, Souza SA, Chen R, Richmond-Crum SM, Grandinetti A & Shikuma C. Elevated blood pressure in HIV-infected individuals receiving highly active antiretroviral therapy. HIV Clinical Trials 2003; 4:411-416.
13. Gazzaruso C, Bruno R, Garzaniti A, Giordanetti S, Fratino P, Sacchi P & Filice G. Hypertension among HIV patients: prevalence and relationships to insulin resistance and metabolic syndrome. Journal of Hypertension 2003; 21:1377-1382.
14. Sattler FR, Qian D, Louie S, Johnson D, Briggs W, DeQuattro V & Dube MP. Elevated blood pressure in subjects with lipodystrophy. AIDS 2001; 15:2001-2010.
15. Benetos A, Rudnichi A, Safar M & Guize L. Pulse pressure and cardiovascular mortality in normotensive and hypertensive subjects. Hypertension 1998; 32:560-564.
16. Nichols WW & O'Rourke MF. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles. 5th edn 2005; London: Edward Arnold.
17. Westerhof N & O'Rourke MF. Haemodynamic basis for the development of left ventricular failure in systolic hypertension and for its logical therapy. Journal of Hypertension 1995; 13:943-952.
18. Boutouyrie P, Bussy C, Lacolley P, Girerd X, Laloux B & Laurent S. Association between local pulse pressure, mean blood pressure, and large-artery remodeling. Circulation 1999; 100:1387-1393.
19. O'Rourke MF, Pauca A & Jiang XJ. Pulse wave analysis. British Journal of Clinical Pharmacology 2001; 51:507-522.
20. London GM, Blacher J, Pannier B, Guerin AP, Marchais SJ & Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension 2001; 38:434-438.
21. Nurnberger J, Keflioglu-Scheiber A, Opazo Saez AM, Wenzel RR, Philipp T & Schafers RF. Augmentation index is associated with cardiovascular risk. Journal of Hypertension 2002; 20:2407-2414.
22. Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Berent R & Eber B. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation 2004; 109:184-189.
23. Sutinen J, Kannisto K, Korsheninnikova E, Nyman T, Ehrenborg E, Andrew R, Wake DJ, Hamsten A, Walker BR & Yki-Jarvinen H. In the lipodystrophy associated with highly active antiretroviral therapy, pseudo-Gushing's syndrome is associated with increased regeneration of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 in adipose tissue. Diabetologia 2004; 47:1668-1671.
24. Sutinen J, Kannisto K, Korsheninnikova E, Fisher RM, Ehrenborg E, Nyman T, Virkamäki A, Funahashi T, Matsuzawa Y, Vidai H, Hamsten A & Yki-Järvinen H. Effects of rosiglitazone on gene expression in subcutaneous adipose tissue in highly active antiretroviral therapy-associated lipodystrophy. American Journal of Physiology: Endocrinology and Metabolism 2004; 286:E941-E949.
25. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M & Yki-Järvinen H. Rosiglitazone in the treatment of HAART-associated lipodystrophy-a randomized double-blind placebo-controlled study. Antiviral Therapy 2003; 8:199-207.
26. Kannisto K, Sutinen J, Korsheninnikova E, Fisher RM, Ehrenborg E, Gertow K, Virkamäki A, Nyman T, Vidal H, Hamsten A & Yki-Järvinen H. Expression of adipogenic transcription factors, peroxisome proliferator- activated receptor gamma co-activator 1, IL-6 and CD45 in subcutaneous adipose tissue in lipodystrophy associated with highly active antiretroviral therapy. AIDS 2003; 17:1753-1762.
27. Sutinen J, Korsheninnikova E, Funahashi T, Matsuzawa Y, Nyman T & Yki-Järvinen H. Circulating concentration of adiponectin and its expression in subcutaneous adipose tissue in patients with highly active antiretroviral therapy-associated lipodystrophy. The Journal of Clinical Endocrinology and Metabolism 2003; 88:1907-1910.
28. Yki-Järvinen H, Sutinen J, Silveira A, Korsheninnikova E, Fisher RM, Kannisto K, Ehrenborg E, Eriksson P & Hamsten A. Regulation of plasma PAI-1 concentrations in HAART-associated lipodystrophy during rosiglitazone therapy. Arteriosclerosis, Thrombosis, and Vascular Biology 2003; 23:688-694.
29. Wilkinson IB, Fuchs SA, Jansen IM, Spratt JC, Murray GD, Cockcroft JR & Webb DJ. Reproducibility of pulse wave velocity and augmentation index measured by pulse wave analysis. Journal of Hypertension 1998; 16:2079-2084.
30. Nichols WW & Singh BM. Augmentation index as a measure of peripheral vascular disease state. Current Opinion in Cardiology 2002; 17:543-551.
31. Westerbacka J, Wilkinson I, Cockcroft J, Utriainen T, Vehkavaara S & Yki-Järvinen H. Diminished wave reflection in the aorta. A novel physiological action of insulin on large blood vessels. Hypertension 1999; 33:1118-1122.
32. Chen CH, Nevo E, Fetics B, Pak PH, Yin FC, Maughan WL & Kass DA. Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation 1997; 95:1827-1836.
33. Karamanoglu M, O'Rourke MF, Avolio AP & Kelly RP. An analysis of the relationship between central aortic and peripheral upper limb pressure waves in man. European Heart Journal 1993; 14:160-167.
34. Wilkinson IB, Mohammad NH, Tyrrell S, Hall IR, Webb DJ, Paul VE, Levy T & Cockcroft JR. Heart rate dependency of pulse pressure amplification and arterial stiffness. American Journal of Hypertension 2002; 15:24-30.
35. Friedewald WT, Levy RI & Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clinical Chemistry 1972; 18:499-502.
36. World Health Organization. Measuring Obesity: Classification and Description of Anthropometric Data. 1988. Copenhagen: WHO.
37. Lukaski HC, Johnson PE, Bolonchuk WW & Lykken GI. Assessment of fat-free mass using bioelectrical impedance measurements of the human body. American Journal of Clinical Nutrition 1985; 41:810-817.
38. Nichols WW. Clinical measurement of arterial stiffness obtained from noninvasive pressure waveforms. American Journal of Hypertension 2005; 18:3S-10S.
39. Sutinen J, Häkkinen AM, Westerbacka J, Seppälä-Lindroos A, Vehkavaara S, Halavaara J, Järvinen A, Ristola M & Yki-Järvinen H. Increased fat accumulation in the liver in HIV-infected patients with antiretroviral therapy-associated lipodystrophy. AIDS 2002; 16:2183-2193.
40. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). Journal of American Medical Association 2001; 285:2486-2497.
41. Alberti KG & Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabetic Medicine 1998; 15:539-553.
42. Lehto S, Rönnemaa T, Pyörälä K & Laakso M. Cardiovascular risk factors clustering with endogenous hyperinsulinaemia predict death from coronary heart disease in patients with Type II diabetes. Diabetologia 2000; 43:148-155.
43. Lempiäinen P, Mykkänen L, Pyörälä K, Laakso M & Kuusisto J. Insulin resistance syndrome predicts coronary heart disease events in elderly nondiabetic men. Circulation 1999; 100:123-128.
44. Meigs JB, D'Agostino RB, Sr., Wilson PW, Cupples LA, Nathan DM & Singer DE. Risk variable clustering in the insulin resistance syndrome. The Framingham Offspring Study. Diabetes 1997; 46:1594-1600.
45. Edwards KL, Austin MA, Newman B, Mayer E, Krauss RM & Selby JV. Multivariate analysis of the insulin resistance syndrome in women. Arteriosclerosis and Thrombosis 1994; 14:1940-1945.
46. Hall JE. Pathophysiology of obesity hypertension. Current Hypertension Reports 2000; 2:139-147.
47. Ferrannini E. Physiological and metabolic consequences of obesity. Metabolism 1995; 44:15-17.
48. Hsue PY, Lo JC, Franklin A, Bolger AF, Martin JN, Deeks SG & Waters DD. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109:1603-1608.
49. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L & Daley J. Severe premature coronary artery disease with protease inhibitors. Lancet 1998; 351:1328.
50. Dressman J, Kincer J, Matveev SV, Guo L, Greenberg RN, Guerin T, Meade D, Li XA, Zhu W, Uittenbogaard A, Wilson ME & Smart EJ. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. The Journal of Clinical Investigation 2003; 111:389-397.
51. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR & Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. British Medical Journal 2000; 321:199-204.
52. Thom DH, Grayston JT, Siscovick DS, Wang SP, Weiss NS & Daling JR. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease. Journal of American Medical Association 1992; 268:68-72.
53. Zhu J, Quyyumi AA, Norman JE, Csako G & Epstein SE. Cytomegalovirus in the pathogenesis of atherosclerosis: the role of inflammation as reflected by elevated C-reactive protein levels. Journal of the American College of Cardiology 1999; 34:1738-1743.
54. Hazenberg MD, Stuart JW, Otto SA, Borleffs JC, Boucher CA, de Boer RJ, Miedema F & Hamann D. T-cell division in human immunodeficiency virus (HIV)-1 infection is mainly due to immune activation: a longitudinal analysis in patients before and during highly active antiretroviral therapy (HAART). Blood 2000; 95:249-255.
55. Barbaro G, Barbarini G & Pellicelli AM. HIV-associated coronary arteritis in a patient with fatal myocardial infarction. New England Journal of Medicine 2001; 344:1799-1800.
56. Chi D, Henry J, Kelley J, Thorpe R, Smith JK & Krishnaswamy G. The effects of HIV infection on endothelial function. Endothelium 2000; 7:223-242.
57. Berger O, Gan X, Gujuluva C, Burns AR, Sulur G, Stins M, Way D, Witte M, Weinand M, Said J, Kim KS, Taub D, Graves MC & Fiala M. CXC and CC chemokine receptors on coronary and brain endothelia. Molecular Medicine 1999;5:795-805.
58. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maachi M, Girard PM, Rozenbaum W, Levan P & Capeau J. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance. Lancet 2002; 359:1026-1031.
59. Nolan D, Hammond E, Martin A, Taylor L, Herrmann S, McKinnon E, Metcalf C, Latham B & Mallal S. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17:1329-1338.
60. Fauvel J, Bonnet E, Ruidavets JB, Ferrieres J, Toffoletti A, Massip P, Chap H & Perret B. An interaction between apo C-III variants and protease inhibitors contributes to high triglyceride/low HDL levels in treated HIV patients. AIDS 2001; 15:2397-2406.